Tag: Argx 117

According to preclinical studies and initial clinical data, ARGX-117, now known as empasiprubart, can reduce free circulating C2 levels by up to 99%. This powerful effect is key to understanding what is the mechanism of action of argx 117, a novel therapeutic strategy for treating complement-mediated autoimmune diseases.

Over 100 autoimmune diseases exist, impacting millions of people worldwide, with many lacking targeted therapies that address the root cause of inflammation. This is where new therapeutic approaches like **empasiprubart** are making an impact by offering a targeted strategy to modulate the immune system.